Delivering Value To Those We Serve

Overview

Recent News

Date Title and Summary
Toggle Summary Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc.
Name Change Reflects Company’s Focus on Neurology, Orphan and Specialty Businesses LAKE FOREST, Ill. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name
Toggle Summary Depomed Announces Second-Quarter 2018 Financial Results
-- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End -- -- Announces Agreement with PDL BioPharma to Monetize Royalty Stream;
Toggle Summary Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018
LAKE FOREST, Ill. , July 09, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018 , before the open of markets. Following the announcement, the Company will host a conference call beginning at

Upcoming Events

There are currently no events to display.

Recent SEC Filings

Filing date Description Form Filing Group View

8-K12B

8-K12B
Other
View HTML

Post-effective amendment to an S-Type filing

POS AM
Registration Statements
View HTML

Post-effective amendment to an S-8 filing

S-8 POS
Registration Statements
View HTML

Post-effective amendment to an S-8 filing

S-8 POS
Registration Statements
View HTML

Post-effective amendment to an S-8 filing

S-8 POS
Registration Statements
View HTML

IR Contact

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com
 

Independent Registered Public Accounting Firm

Ernst & Young LLP
Palo Alto, CA
 

Investor Relations Contact

John B. Thomas
SVP, Investor Relations & Corporate Communications
jthomas@assertiotx.com